1-chloro-4-methoxybutane

We are 1-chloro-4-methoxybutane CAS:17913-18-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  1-chloro-4-methoxybutane
CAS.NO:17913-18-7
Molecular Formula:C5H11ClO
Molecular Weight:122.59300

Synonyms:
4-Chlorobutyl methyl ether
1-Chloro-4-methoxybutane
4-(methoxy)-1-chlorobutane
4-Methoxybutyl Chloride
Butane,1-chloro-4-methoxy
4-chloro-1-methoxybutane
Ether,4-chlorobutyl methyl
1-chlor-4-methoxybutan
methyl 4-chlorobutyl ether

Physical and Chemical Properties:
Density: 0.951 g / cm3
Boiling point: 138.3ºC at 760 mmHg
Flash point: 47.8 ± 17.9 ° C
Refractive index: 1.408

Specification:
Appearance:Colorless liquid
Purity:≥99.0%
Moisture Content: <0.1%
Impurity: <0.4%
Loss On Drying: 0.2%

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place.
Application:  
Pharmaceutical Intermediates, APIs,fluvoxamine maleate intermediate.

Related News: In addition, although the API and intermediate industries are capital-intensive and technology-intensive industries, new competitors are still joining.Ethyl Silicate 40 CAS:11099-06-2 or 68412-37-3 In addition, although the API and intermediate industries are capital-intensive and technology-intensive industries, new competitors are still joining.4-(1,2-Benzothiazol-3-yl)-1-[(3aR,7aR)-octahydro-2H-isoindol-2-yl ]piperazin-1-ium-1-sulfonate China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.2,6-Difluorobenzaldehyde China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.The Breakthrough Designation for the iLet Bionic Pancreas System contemplates configurations with most insulin analogs approved for pumping as well as dasiglucagon, Zealand Pharma’s stable pumpable glucagon analog, which has a unique stability profile in a ready-to-use aqueous solution.